Adicet Bio Files 8-K Report

TL;DR

Adicet Bio filed an 8-K, mostly standard disclosures. Keep an eye out for details.

AI Summary

On June 24, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Adicet Bio is providing updated information to the SEC, which could include financial details or other corporate events relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific negative or positive material information disclosed.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• resTORbio, Inc. (company) — Former company name
• June 24, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20240624.htm (8-K) — 42KB
• acet-ex99_1.htm (EX-99.1) — 23KB
• 0000950170-24-076460.txt ( ) — 183KB
• acet-20240624.xsd (EX-101.SCH) — 24KB
• acet-20240624_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 24, 2024, Adicet Bio, Inc. (the "Company") issued a press release titled "Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On June 24, 2024, the Company announced that the U.S. Food and Drug Administration cleared the Company's Investigational New Drug application to evaluate ADI-270, an armored allogeneic "off-the-shelf" gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma (RCC). The Company plans to initiate a Phase 1 multicenter, open-label clinical trial to assess the safety and anti-tumor activity of ADI-270 in RCC patients in the second half of 2024 and share preliminary clinical data in the first half of 2025. The trial is designed to investigate ADI-270 as monotherapy in adults with relapsed or refractory clear cell RCC. Following lymphodepletion, patients will be eligible to receive a single dose of ADI-270 with a starting dose level of 3E8 CAR+ cells. Subject to meeting protocol defined criteria, patients enrolled in the study may be eligible to receive a second dose of ADI-270. The dose escalation and dose expansion portions of the trial will evaluate safety, tolerability and pharmacokinetics as well as anti-tumor activity as assessed by overall response rate, duration of response and disease control rate.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on June 24, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADICET BIO, INC. Date: June 24, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR